Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Drug resistance to targeted therapies: déjà vu all over again.

Literature DB >> 24910388

Drug resistance to targeted therapies: déjà vu all over again.

Abstract

A major limitation of targeted anticancer therapies is intrinsic or acquired resistance. This review emphasizes similarities in the mechanisms of resistance to endocrine therapies in breast cancer and those seen with the new generation of targeted cancer therapeutics. Resistance to single-agent cancer therapeutics is frequently the result of reactivation of the signaling pathway, indicating that a major limitation of targeted agents lies in their inability to fully block the cancer-relevant signaling pathway. The development of mechanism-based combinations of targeted therapies together with non-invasive molecular disease monitoring is a logical way forward to delay and ultimately overcome drug resistance development.

Entities: Disease

Keywords: Anticancer therapy; Drug combinations; Drug resistance; Endocrine therapy; Pathway reactivation; Targeted therapy

Mesh：

Substances：
Antineoplastic Agents

Year: 2014 PMID： 24910388 PMCID： PMC5528618 DOI： 10.1016/j.molonc.2014.05.004

Source DB: PubMed Journal: Mol Oncol ISSN： 1574-7891 Impact factor: 6.603

126 in total

1. Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases.

Authors: Seiji Yano; Emiko Nakataki; Shinsaku Ohtsuka; Mami Inayama; Hideki Tomimoto; Nobutaka Edakuni; Soji Kakiuchi; Naoki Nishikubo; Hiroaki Muguruma; Saburo Sone
Journal: Oncol Res Date: 2005 Impact factor: 5.574

2. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer.

Authors: Michele De Laurentiis; Grazia Arpino; Erminia Massarelli; Angela Ruggiero; Chiara Carlomagno; Fortunato Ciardiello; Giampaolo Tortora; Diego D'Agostino; Francesca Caputo; Giuseppe Cancello; Emilia Montagna; Luca Malorni; Luigia Zinno; Rossella Lauria; Angelo Raffaele Bianco; Sabino De Placido
Journal: Clin Cancer Res Date: 2005-07-01 Impact factor: 12.531

Review 3. Biological determinants of endocrine resistance in breast cancer.

Authors: Elizabeth A Musgrove; Robert L Sutherland
Journal: Nat Rev Cancer Date: 2009-09 Impact factor: 60.716

4. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.

Authors: M E Gorre; M Mohammed; K Ellwood; N Hsu; R Paquette; P N Rao; C L Sawyers
Journal: Science Date: 2001-06-21 Impact factor: 47.728

5. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

Authors: Jeffrey A Sosman; Kevin B Kim; Lynn Schuchter; Rene Gonzalez; Anna C Pavlick; Jeffrey S Weber; Grant A McArthur; Thomas E Hutson; Stergios J Moschos; Keith T Flaherty; Peter Hersey; Richard Kefford; Donald Lawrence; Igor Puzanov; Karl D Lewis; Ravi K Amaravadi; Bartosz Chmielowski; H Jeffrey Lawrence; Yu Shyr; Fei Ye; Jiang Li; Keith B Nolop; Richard J Lee; Andrew K Joe; Antoni Ribas
Journal: N Engl J Med Date: 2012-02-23 Impact factor: 91.245

6. Cancer. Addiction to oncogenes--the Achilles heal of cancer.

Authors: I Bernard Weinstein
Journal: Science Date: 2002-07-05 Impact factor: 47.728

7. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity.

Authors: M Scaltriti; C Verma; M Guzman; J Jimenez; J L Parra; K Pedersen; D J Smith; S Landolfi; S Ramon y Cajal; J Arribas; J Baselga
Journal: Oncogene Date: 2008-12-08 Impact factor: 9.867

8. Epithelial-to-mesenchymal transition rewires the molecular path to PI3K-dependent proliferation.

Authors: Megan B Salt; Sourav Bandyopadhyay; Frank McCormick
Journal: Cancer Discov Date: 2013-12-03 Impact factor: 39.397

9. Transient over-expression of estrogen receptor-α in breast cancer cells promotes cell survival and estrogen-independent growth.

Authors: Robert S Tolhurst; Ross S Thomas; Fiona J Kyle; Hetal Patel; Manikandan Periyasamy; Andrew Photiou; Paul T R Thiruchelvam; Chun-Fui Lai; Marwa Al-Sabbagh; Rosemary A Fisher; Sayka Barry; Tatjana Crnogorac-Jurcevic; Lesley-Ann Martin; Mitch Dowsett; R Charles Coombes; Tahereh Kamalati; Simak Ali; Laki Buluwela
Journal: Breast Cancer Res Treat Date: 2010-08-22 Impact factor: 4.872

10. Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer.

Authors: Elizabeth Iorns; Nicholas C Turner; Richard Elliott; Nelofer Syed; Ornella Garrone; Milena Gasco; Andrew N J Tutt; Tim Crook; Christopher J Lord; Alan Ashworth
Journal: Cancer Cell Date: 2008-02 Impact factor: 31.743

87 in total

1. Mitotic Exit Dysfunction through the Deregulation of APC/C Characterizes Cisplatin-Resistant State in Epithelial Ovarian Cancer.

Authors: Anil Belur Nagaraj; Olga Kovalenko; Rita Avelar; Peronne Joseph; Annalyn Brown; Arshia Surti; Sandra Mantilla; Analisa DiFeo
Journal: Clin Cancer Res Date: 2018-04-13 Impact factor: 12.531

Drug resistance to targeted therapies: déjà vu all over again.

1. Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases.

2. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer.

Review 3. Biological determinants of endocrine resistance in breast cancer.

4. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.

5. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

6. Cancer. Addiction to oncogenes--the Achilles heal of cancer.

7. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity.

8. Epithelial-to-mesenchymal transition rewires the molecular path to PI3K-dependent proliferation.

9. Transient over-expression of estrogen receptor-α in breast cancer cells promotes cell survival and estrogen-independent growth.

10. Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer.

1. Mitotic Exit Dysfunction through the Deregulation of APC/C Characterizes Cisplatin-Resistant State in Epithelial Ovarian Cancer.

Review 2. Recent and current clinical trials in canine appendicular osteosarcoma.

Review 3. Biologics in gastrointestinal and pancreatic neuroendocrine tumors.

Review 4. Opportunities and challenges provided by crosstalk between signalling pathways in cancer.

5. Innovative clinical trials for development of personalized cancer medicine.

6. Cancer drug resistance: old concept, novel solutions required.

Review 7. Drug resistance to targeted therapies: déjà vu all over again.

Review 8. Metastatic gastric cancer treatment: Second line and beyond.

Review 9. Vismodegib: A Review in Advanced Basal Cell Carcinoma.

10. Overcoming Resistance to Targeted Anticancer Therapies through Small-Molecule-Mediated MEK Degradation.